GLP-1 Agonists: Clinical Evidence for Weight Management
Artificial sweeteners insulin sensitivity is a critical factor in metabolic health during GLP-1 therapy. Recent evidence shows these sweeteners may impair insulin sensitivity independently of calories. Understanding this helps optimize weight management…
GLP-1 Clinical Evidence: Adolescent Metabolic Health
Adolescent metabolic health is critical for preventing obesity and type 2 diabetes. GLP-1 clinical evidence supports early intervention in youth with insulin resistance. Family medicine clinicians can apply consensus guidelines to improve outcomes.
Cannabidiol as a Modulator of the Gut-Liver Axis: Clinical and Pharmacological Insights
CBD gut-liver axis modulation shows promise in treating hepatic and metabolic disorders. This non-intoxicating compound may improve gut barrier function and reduce inflammation. Understanding CBD's role offers new perspectives for metabolic syndrome…
New Research on CBD and CBG for Fatty Liver Disease
Emerging research on cbd and cbg fatty liver disease shows potential therapeutic benefits beyond lifestyle modification. These non-intoxicating cannabis compounds may reduce liver fat and improve hepatic health. While promising, clinical trials are…